CA
NZ
UK
AU
IND
US
…
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosure about AngioSoma Inc (GSTC.PK) is limited, and the company does not provide clear, verifiable information about its core business, products, or financial condition. Potential long-term growth drivers are therefore unclear; investors may be attracted only by speculative upside should management later disclose viable assets, secure partnerships, or achieve operational milestones.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 |
| Income before tax | -1.49M | -1.49M | -1.49M | -1.49M | -9.80M |
| Net income | -1.49M | -1.49M | -1.64M | -1.49M | -9.67M |
| Selling general administrative | 1.27M | 1.27M | 1.27M | 1.26M | 9.09M |
| Selling and marketing expenses | - | 0.60M | - | - | - |
| Gross profit | - | 0.00M | 0.00M | 0.00M | -0.00M |
| Reconciled depreciation | - | - | 0.00M | 0.00M | 0.00M |
| Ebit | -1.27M | -1.27M | -1.27M | -1.27M | -9.09M |
| Ebitda | -1.27M | -1.27M | -1.42M | -1.26M | -9.51M |
| Depreciation and amortization | 0.00M | 0.00M | -0.15M | 0.00M | -0.42M |
| Operating income | -1.27M | -1.27M | -1.27M | -1.26M | -9.09M |
| Other operating expenses | 1.27M | 1.27M | 1.27M | 1.26M | 9.09M |
| Interest expense | 0.07M | 0.07M | 0.07M | 0.07M | 0.29M |
| Net interest income | - | -0.09M | -0.07M | -0.07M | -0.29M |
| Income tax expense | -0.00M | -0.00M | 0.15M | 0.15M | -0.13M |
| Total revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.27M | 1.27M | 1.27M | 1.26M | 9.09M |
| Cost of revenue | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total other income expense net | -0.22M | -0.22M | -0.22M | -0.22M | -0.71M |
| Net income from continuing ops | - | -1.95M | -1.49M | -1.49M | -9.80M |
| Net income applicable to common shares | - | - | -1.49M | -1.49M | -9.80M |
| Breakdown | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 |
| Total assets | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Other current assets | - | - | 0.00M | 0.00M | - |
| Total liab | 1.43M | 1.43M | 1.20M | 1.20M | 0.73M |
| Total stockholder equity | - | -1.43M | -1.19M | -1.19M | -0.73M |
| Other current liab | 0.86M | 0.74M | 0.80M | 0.80M | 0.40M |
| Common stock | 1.00M | 1.00M | 0.72M | 0.72M | 0.56M |
| Capital stock | - | 1.00M | 0.72M | 0.72M | 0.56M |
| Retained earnings | -20.45M | -20.45M | -18.50M | -18.50M | -17.02M |
| Cash | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Total current liabilities | 1.43M | 1.43M | 1.20M | 1.20M | 0.73M |
| Current deferred revenue | -0.11M | -0.11M | 0.00M | 0.00M | - |
| Net debt | 0.36M | 0.37M | 0.01M | 0.01M | 0.10M |
| Short term debt | 0.36M | 0.37M | 0.02M | 0.02M | 0.11M |
| Short long term debt | - | 0.36M | 0.02M | 0.02M | 0.17M |
| Short long term debt total | 0.36M | 0.37M | 0.02M | 0.02M | 0.11M |
| Other stockholder equity | 19.46M | 18.02M | 16.59M | 16.58M | 15.73M |
| Total current assets | - | 0.00M | 0.01M | 0.01M | 0.01M |
| Net tangible assets | - | - | -1.20M | -1.20M | -0.73M |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 0.33M | 0.33M | 0.38M | 0.38M | 0.22M |
| Accumulated other comprehensive income | -1.43M | 0.00M | - | 0.01M | - |
| Non current assets total | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-12-31 | 2022-09-30 | 2021-12-31 | 2021-09-30 |
| Investments | - | - | - | 0.00M | 0.00M |
| Change to liabilities | - | 0.43M | 0.43M | 0.20M | 0.20M |
| Net borrowings | 0.06M | 0.01M | 0.01M | 0.10M | 0.10M |
| Total cash from financing activities | 0.20M | 0.33M | 0.33M | 0.68M | 0.68M |
| Change to operating activities | - | 0.01M | 0.01M | 0.02M | 0.02M |
| Net income | -1.95M | -1.49M | -1.49M | -9.80M | -9.80M |
| Change in cash | -0.01M | 0.00M | 0.00M | -0.08M | -0.08M |
| Begin period cash flow | 0.01M | 0.01M | 0.01M | 0.08M | 0.08M |
| End period cash flow | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M |
| Total cash from operating activities | -0.21M | -0.33M | -0.33M | -0.75M | -0.75M |
| Issuance of capital stock | 0.15M | 0.32M | 0.32M | 0.58M | 0.58M |
| Depreciation | 0.03M | 0.05M | 0.05M | 0.00M | 0.00M |
| Change to inventory | - | - | - | 0.00M | 0.00M |
| Other cashflows from financing activities | 0.07M | 0.32M | 0.32M | 0.18M | 0.08M |
| Change to netincome | - | 0.66M | 0.66M | 8.55M | 8.55M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.45M | 0.44M | 0.44M | 0.22M | 0.22M |
| Stock based compensation | 1.27M | 0.51M | 0.51M | 8.13M | 8.13M |
| Other non cash items | 0.06M | 0.15M | 0.15M | 0.69M | 0.69M |
| Free cash flow | -0.21M | -0.33M | -0.33M | -0.75M | -0.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GSTC AngioSoma Inc |
- -% |
0.00 | - | - | 78200.54 | - | 124103.10 | -0.97 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.
1280 Lexington Avenue, New York, NY, United States, 10028
509-531-1671
| Name | Title | Year Born |
|---|---|---|
| Mr. James C. Katzaroff | Pres, CEO, Sec., Principal Exec. Officer & Chairman | 1957 |
| Mr. Robert Hale Chicoski CPA | CFO, Treasurer & Principal Financial Officer | 1943 |
| Mr. William J. Farley B.Sc. | Devel. Officer & Director | 1955 |
| Mr. Steven F. Penderghast | Commercial Officer & Director | NA |
| Ms. Brooke Greenwald | Chief Marketing Officer | NA |
| Mr. David Croom | Exec. VP | NA |
| Mr. James C. Katzaroff | President, CEO, Secretary, Principal Executive Officer & Chairman of the Board | 1957 |
| Mr. David Croom | Executive Vice President | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...